The ingenuity pathway analysis (IPA) of publicly available human datasets from patients with NAFLD/NASH consistently predicted the possible association of SP1 with NASH incidence (GSE89632) and fibrotic disease (GSE130970) and KLF2 association with a particular cohort with advanced fibrosis (GSE130970) [160]. Here, KLF2 is linked to metabolic dysfunction-associated steatotic liver disease.